When was Onyx founded?

Onyx was founded in 2024 and raised its 1st funding round 2 years after it was founded.

Where is Onyx located?

Onyx is headquartered in Berkeley, United States.

Is Onyx a funded company?

Onyx is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Feb 13, 2026.

When was the latest funding round of Onyx?

Onyx's latest funding was a $***** Series A round on Feb 13, 2026, with participation from 0 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $2.14B in funding in 2026 to date.

Where does Onyx rank among its competitors?

Onyx ranks 294th amongst 439 active competitors, of which 176 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Onyx, which secured $8M in Feb, 2026.

Who are the top competitors of Onyx?

Onyx's top competitors include argenx, Sana Biotechnology and Schrodinger. Among them, Onyx secured the most recent funding round in February, 2026.

Onyx - 2026 Company Profile, Funding & Competitors

Company Details

Developer of an AI platform for precision medicine research studies. The platform integrates multiomics data with longitudinal patient records to deeply profile autoimmune diseases. Members can join research studies by sharing health records and samples. Life scientists and AI researchers analyze samples and health records to develop new medicines. Members may receive a portion of revenue generated using their data.

Website: www.onyx.bio
Phone Number: +1 **********

Key Metrics

Founded Year

2024

Location

Berkeley, United States

Stage

Series A

Total Funding

$8M in 1 round

Latest Funding Round

Series A, Feb 13, 2026, $*****

Ranked

294^th among 439 active competitors

Similar Companies

argenx & 496 more

View Onyx's full profile

Onyx has raised a total funding of $8M over 1 round.

Here is the list of recent funding rounds of Onyx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 13, 2026	7307187	Series A	2706294	2275349	8700590	9572338

Access funding benchmarks and valuations. Sign up today!

View details of Onyx's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Onyx include argenx, Sana Biotechnology and Schrodinger. Here is the list of Top 10 competitors of Onyx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Omnes Capital & 20 others	76/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gatesfoundation, WuXi AppTec & 16 others	74/100
4th	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 46 others	72/100
5th	Healx 2014, Cambridge (United Kingdom), Series C	AI-powered drug discovery platform to treat rare diseases	$115M	Atomico, Balderton Capital & 18 others	69/100
6th	Dren Bio 2019, San Carlos (United States), Series B	Developer of therapeutic antibodies for the treatment of cancer, autoimmune, and other serious diseases	$156M	Aisling Capital, Taiho Ventures & 13 others	68/100
7th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Novartis Venture Fund & 16 others	67/100
8th	Kiniksa Pharmaceuticals 2015, Lexington (United States), Public	Developer of therapeutics for multiple diseases treatment	$320M	Fidelity Investments, Sofinnova Investments ... & 8 others	67/100
9th	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	SoftBank Vision Fund, Tencent & 25 others	67/100
10th	Autolus 2015, London (United Kingdom), Public	Developer of engineered T-cell immunotherapy for cancer and auto-immune diseases	$181M	Syncona, 4Bio Capital & 7 others	65/100
294th	Onyx 2024, Berkeley (United States), Series A	Developer of an AI platform for precision medicine research studies	$8M	-	26/100